Fujian Guizhen Tang Pharmaceutical

Fujian Guizhen Tang Pharmaceutical is a prominent Chinese pharmaceutical company specializing in Traditional Chinese Medicine (TCM), specifically products derived from black bear bile. Founded in 2000 and based in Huian, Fujian, the company operates one of China's largest black bear breeding and bile extraction facilities. Its product portfolio includes bear bile powder, capsules, and various TCM formulations aimed at treating liver conditions and inflammatory diseases. The company gained significant international notoriety and faced public backlash due to its practice of live bile milking, which led to the withdrawal of its initial public offering (IPO) plans in 2012. Despite the controversy, it remains a major player in the domestic TCM market for bear-bile-based therapeutics.